{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T22:18:02Z","timestamp":1784585882943,"version":"3.55.0"},"reference-count":88,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T00:00:00Z","timestamp":1530057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Type 2 Diabetes Mellitus (T2DM) is the most common form of diabetes mellitus and accounts for about 95% of all diabetes cases. Many newer oral as well as parenteral antidiabetic drugs have been introduced in to the market in recent years to control hyperglycemic conditions in diabetes patients and many of these drugs produce potential side effects in diabetes patients. Hence, this systematic review was aimed to analyze and compare the efficacy and safety of oral antidiabetic agents in controlling HbA1c in T2DM patients, that were approved by the United States-Food and Drug Administration (US-FDA) from 2013 to 2017. All randomized controlled, double-blind trials published in English during the search period involving the newer antidiabetic agents were selected. In the outcome assessment comparison, semaglutide demonstrated the highest efficacy in lowering HbA1c, with a 1.6% reduction (p &lt; 0.0001) when given at a dose of 1.0 mg. The safety profile of all the agents as compared to placebo or control were similar, with no or slight increase in the occurrence of adverse events (AEs) but no fatal reaction was reported. The most common AEs of all the antidiabetic agents were gastrointestinal in nature, with several cases of hypoglycemic events. However, among all these agents, semaglutide seems to be the most efficacious drug to improve glycemic control in terms of HbA1c. Alogliptin has the least overall frequency of AEs compared to other treatment groups.<\/jats:p>","DOI":"10.3390\/pharmacy6030057","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T11:02:05Z","timestamp":1530097325000},"page":"57","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Systematic Review of Efficacy and Safety of Newer Antidiabetic Drugs Approved from 2013 to 2017 in Controlling HbA1c in Diabetes Patients"],"prefix":"10.3390","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1844-8108","authenticated-orcid":false,"given":"Sivanandy","family":"Palanisamy","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, International Medical University, Kuala Lumpur 57000, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Lau Hie","family":"Yien","sequence":"additional","affiliation":[{"name":"School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling Wen","family":"Shi","sequence":"additional","affiliation":[{"name":"School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Low Yi","family":"Si","sequence":"additional","affiliation":[{"name":"School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"See Hui","family":"Qi","sequence":"additional","affiliation":[{"name":"School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Soon Cheau","family":"Ling","sequence":"additional","affiliation":[{"name":"School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng Wai","family":"Lun","sequence":"additional","affiliation":[{"name":"School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yap Nee","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,6,27]]},"reference":[{"key":"ref_1","first-page":"126","article-title":"Tanzeum (Albiglutide): A once-weekly GLP-1 receptor agonist subcutaneous injection approved for the treatment of patients with type 2 diabetes","volume":"8","author":"Fala","year":"2015","journal-title":"Am. Health Drug Benefits"},{"key":"ref_2","unstructured":"Centers for Disease Control and Prevention (2018, April 10). National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, Available online: https:\/\/www.cdc.gov\/diabetes\/pubs\/pdf\/ndfs_2011.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5001\/omj.2012.68","article-title":"Type 2 diabetes mellitus: A review of current trends","volume":"27","author":"Olokoba","year":"2012","journal-title":"Oman Med. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.metabol.2010.09.010","article-title":"Management of type 2 diabetes: Evolving strategies for the treatment of patients with type 2 diabetes","volume":"60","author":"Nyenwe","year":"2011","journal-title":"Metabolism"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.2522\/ptj.20080008","article-title":"Diabetes-related microvascular and macrovascular diseases in the physical therapy setting","volume":"88","author":"Cade","year":"2008","journal-title":"Phys. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4103\/2230-8210.183480","article-title":"Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum?","volume":"20","author":"Chawla","year":"2016","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1900\/RDS.2012.9.6","article-title":"Genetic and environmental factors associated with type 2 diabetes and diabetic vascular complications","volume":"9","author":"Murea","year":"2012","journal-title":"Rev. Diabet. Stud."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2337\/diabetes.49.12.2201","article-title":"Parental transmission of type 2 diabetes: The Framingham Offspring Study","volume":"49","author":"Meigs","year":"2000","journal-title":"Diabetes"},{"key":"ref_9","unstructured":"National Institute for Health and Clinical Excellence (2018, April 10). Type 2 Diabetes in Adults: Management. Available online: https:\/\/www.nice.org.uk\/guidance\/ng28."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc12-0413","article-title":"Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"35","author":"Inzucchi","year":"2012","journal-title":"Diabetes Care"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"536","DOI":"10.4158\/EP13176.CS","article-title":"American Association of Clinical Endocrinologists\u2019 comprehensive diabetes management algorithm 2013 consensus statement","volume":"19","author":"Garber","year":"2013","journal-title":"Endocr. Pract."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12933-016-0407-4","article-title":"Efficacy and safety of canagliflozin in combination with insulin: A double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus","volume":"15","author":"Inagaki","year":"2016","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/dom.12054","article-title":"Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"15","author":"Stenlof","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.12684","article-title":"Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin","volume":"18","author":"Rodbard","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12933-017-0517-7","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes based on history of cardiovascular disease or cardiovascular risk factors: A post hoc analysis of pooled data","volume":"16","author":"Davies","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Sha, S., Devineni, D., Ghosh, A., Polidori, D., Hompesch, M., Arnolds, S., Morrow, L., Spitzer, H., Demarest, K., and Rothenberg, P. (2014). Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0105638"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12837","article-title":"Randomized, double-blind, phase III study to evaluate the efficacy and safety of once-daily treatment with alogliptin and metformin hydrochloride in Japanese patients with type 2 diabetes","volume":"19","author":"Kaku","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00228-016-2175-1","article-title":"The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus","volume":"73","author":"Dudkowski","year":"2017","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"893","DOI":"10.5551\/jat.18333","article-title":"Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: The study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A)","volume":"20","author":"Katakami","year":"2013","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1161\/CIRCULATIONAHA.111.041418","article-title":"Long-term dipepti- dyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis","volume":"124","author":"Shah","year":"2011","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/FJC.0b013e31821e5626","article-title":"DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein e-deficient mice","volume":"58","author":"Ta","year":"2011","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Li, F.F., Gao, G., Li, Q., Zhu, H.H., Su, X.F., Wu, J.D., Lei, Y., and Ma, J. (2016). Influence of dapagliflozin on glycemic variations in patients with newly diagnosed type 2 diabetes mellitus. J. Diabetes Res., 5347262.","DOI":"10.1155\/2016\/5347262"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.2337\/dc14-0315","article-title":"Dapagliflozin\u2019s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension","volume":"38","author":"Cefalu","year":"2015","journal-title":"Diabetes Care"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/jdi.12453","article-title":"Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period","volume":"7","author":"Araki","year":"2016","journal-title":"J. Diabetes Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.clinthera.2013.11.002","article-title":"Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: A randomized, blinded, prospective phase III study","volume":"36","author":"Ji","year":"2014","journal-title":"Clin. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/dom.12503","article-title":"Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: A 78-week randomized, double-blind, placebo-controlled trial","volume":"17","author":"Rosenstock","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1479164115616901","article-title":"Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus","volume":"13","author":"Neeland","year":"2016","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/dom.12494","article-title":"Empagliflozin as adjunct to insulin in patients with type 1 diabetes: A 4-week, randomized, placebo-controlled trial (EASE-1)","volume":"17","author":"Pieber","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12933-015-0314-0","article-title":"Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-na\u00efve patients with type 2 diabetes: A double-blind extension of a Phase III randomized controlled trial","volume":"14","author":"Roden","year":"2015","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12933-014-0169-9","article-title":"Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled, 4-week study","volume":"14","author":"Nishimura","year":"2015","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1475-2840-12-129","article-title":"Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control","volume":"12","author":"Ridderstrale","year":"2013","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_34","first-page":"789","article-title":"Once-weekly albiglutide in the management of type 2 diabetes: Patient considerations","volume":"8","author":"Woodward","year":"2014","journal-title":"Patient Prefer. Adherence"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.2337\/dc09-0366","article-title":"Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing","volume":"32","author":"Rosenstock","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12955-017-0696-7","article-title":"Evaluation of the impact of once weekly dulaglutide on patient-reported outcomes in Japanese patients with type 2 diabetes: Comparisons with liraglutide, insulin glargine, and placebo in two randomized studies","volume":"15","author":"Suzuki","year":"2017","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1507\/endocrj.EJ16-0428","article-title":"Efficacy and safety analyses across 4 subgroups combining low and high age and body mass index groups in Japanese phase 3 studies of dulaglutide 0.75 mg after 26 weeks of treatment","volume":"64","author":"Hamano","year":"2017","journal-title":"Endocr. J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/dom.12660","article-title":"Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment","volume":"18","author":"Umpierrez","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/dom.12634","article-title":"A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8)","volume":"18","author":"Dungan","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1507\/endocrj.EJ15-0518","article-title":"Subgroup analysis of phase 3 studies of dulaglutide in Japanese patients with type 2 diabetes","volume":"63","author":"Onishi","year":"2016","journal-title":"Endocr. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/dom.12602","article-title":"Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52\u2009weeks of treatment in a randomized phase III study","volume":"18","author":"Odawara","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/dom.12540","article-title":"Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and\/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: A randomized, open-label, phase III, non-inferiority study","volume":"17","author":"Araki","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/dom.12534","article-title":"Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: A 26-week randomized phase III study","volume":"17","author":"Miyagawa","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/dom.12479","article-title":"Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2\u2009years in metformin-treated patients with type 2 diabetes (AWARD-5): A randomized, phase III study","volume":"17","author":"Weinstock","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1507\/endocrj.EJ14-0147","article-title":"Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: Dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study","volume":"61","author":"Terauchi","year":"2014","journal-title":"Endocr. J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.2337\/dc13-2761","article-title":"Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5)","volume":"37","author":"Nauck","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/j.1464-5491.2010.03020.x","article-title":"Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: A randomized, double-blind, placebo-controlled trial","volume":"27","author":"Ratner","year":"2010","journal-title":"Diabet. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/dom.12278","article-title":"Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes\u2014A study in both people with type 2 diabetes and healthy subjects","volume":"16","author":"Becker","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.jdiacomp.2014.05.012","article-title":"Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day","volume":"28","author":"Ahren","year":"2014","journal-title":"J. Diabetes Complicat."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.regpep.2013.04.001","article-title":"Effects of lixisenatide once daily on gastric emptying in type 2 diabetes- relationship to postprandial glycemia","volume":"185","author":"Lorenz","year":"2013","journal-title":"Regul. Pept."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/dmrr.2647","article-title":"Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects","volume":"31","author":"Becker","year":"2015","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"475","DOI":"10.21037\/atm.2017.10.09","article-title":"Semaglutide- the \u2018new kid on the block\u2019 in the field of glucagon-like peptide-1 receptor agonists?","volume":"5","author":"Guja","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"505","DOI":"10.21037\/atm.2017.11.10","article-title":"Semaglutide seems to be more effective the other GLP-1Ras","volume":"5","author":"Holst","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): A double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1111\/ijcp.12322","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: A randomised trial","volume":"67","author":"Wilding","year":"2013","journal-title":"Int. J. Clin. Pract."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","article-title":"Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: A randomised trial","volume":"56","author":"Januszewicz","year":"2013","journal-title":"Diabetologia"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jdiacomp.2014.12.016","article-title":"Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus","volume":"29","author":"Wilding","year":"2015","journal-title":"J. Diabetes Complicat."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/jgs.14028","article-title":"Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: A pooled analysis","volume":"64","author":"Sinclair","year":"2016","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/ijcp.12868","article-title":"Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates","volume":"70","author":"John","year":"2016","journal-title":"Int. J. Clin. Pract."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s12325-015-0234-0","article-title":"Pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with type 2 diabetes mellitus","volume":"32","author":"Iijima","year":"2015","journal-title":"Adv. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/dom.12615","article-title":"Apparent subadditivity of the efficacy of initial combination treatments for type 2 diabetes is largely explained by the impact of baseline HbA1c on efficacy","volume":"18","author":"Polidori","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/dom.12273","article-title":"Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone","volume":"16","author":"Forst","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.metabol.2014.07.003","article-title":"Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: Results of a randomized trial","volume":"63","author":"Stein","year":"2014","journal-title":"Metabolism"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/jcph.88","article-title":"Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus","volume":"53","author":"Devineni","year":"2013","journal-title":"J. Clin. Pharmacol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1507\/endocrj.EJ16-0341","article-title":"Comparative analysis of the effects of alogliptin and vildagliptin on glucose metabolism in type 2 diabetes mellitus","volume":"64","author":"Tanaka","year":"2017","journal-title":"Endocr. J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e003277","DOI":"10.1161\/JAHA.112.003277","article-title":"Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients","volume":"2","author":"Ayaori","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/dom.12779","article-title":"Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes","volume":"19","author":"Lundkvist","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2337\/dc13-0387","article-title":"Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes","volume":"36","author":"DeFronzo","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Wie","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-016-0381-x","article-title":"Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: The CANDLE trial","volume":"15","author":"Tanaka","year":"2016","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/dom.12382","article-title":"Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin","volume":"16","author":"Reusch","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s00125-015-3795-1","article-title":"Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"59","author":"Nauck","year":"2016","journal-title":"Diabetologia"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/dme.12328","article-title":"Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)","volume":"31","author":"Bolli","year":"2014","journal-title":"Diabet. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2337\/dc11-1935","article-title":"Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono)","volume":"35","author":"Fonseca","year":"2012","journal-title":"Diabetes Care"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jdiacomp.2014.01.012","article-title":"Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)","volume":"28","author":"Rosenstock","year":"2014","journal-title":"J. Diabetes Complicat."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/dom.12276","article-title":"Pharmacodynamics of the glucagon-like peptide-1 receptor agonist lixisenatide in Japanese and Caucasian patients with type 2 diabetes mellitus poorly controlled on sulphonylureas with\/without metformin","volume":"16","author":"Seino","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.2337\/dc16-0046","article-title":"Efficacy and safety of Lixi Lan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in type 2 diabetes inadequately controlled on Metformin Monotherapy: The LixiLan proof-of-concept randomized trial","volume":"39","author":"Rosenstock","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.2337\/dc12-2454","article-title":"Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by established basal insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.2337\/dc12-2462","article-title":"Adding once-daily lixisenatide for type2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: A 24-week, randomized, placebo-controlled study (GetGoal-Duo 1)","volume":"36","author":"Riddle","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.2337\/dc12-2006","article-title":"Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M)","volume":"36","author":"Ahren","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/dom.12076","article-title":"Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin","volume":"15","author":"Kapitza","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): A 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): A 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahren","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.2337\/dc12-2391","article-title":"Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: Results of a randomized, placebo-controlled study","volume":"36","author":"Polidori","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.2337\/dc13-0663","article-title":"Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes","volume":"36","author":"Ferrannini","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/dom.12305","article-title":"Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5)","volume":"16","author":"Skrivanek","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.jdiacomp.2015.07.003","article-title":"Long-term safety of once-daily lixisenatide in Japanese patients with type 2 diabetes mellitus: GetGoal-Mono-Japan","volume":"29","author":"Seino","year":"2015","journal-title":"J. Diabetes Complicat."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/6\/3\/57\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:10:21Z","timestamp":1760195421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/6\/3\/57"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,27]]},"references-count":88,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,9]]}},"alternative-id":["pharmacy6030057"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy6030057","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,27]]}}}